Weight-loss jabs linked to reduced risk of 42 conditions including dementia
The most comprehensive study of its kind showed that psychotic disorders, infections and dementia were among conditions found to be less likely to occur when using GLP-1RAs, which are found in the medications Saxenda, Wegovy and Mounjaro.
The researchers compared health outcomes for people with diabetes who received usual care with those also given drugs such as liraglutide, semaglutide and tirzepatide. While the team revealed the risk of many conditions was lower for the latter group, the risk of other conditions, including arthritic disorders, was increased.
And the scientists say that the benefits are not just restricted to people with diabetes, suggesting they could also be found in other people using the jabs, such as those who take them to fight obesity.
https://www.theguardian.com/society/2025/jan/20/weight-loss-jabs-linked-to-reduced-risk-of-42-conditions-including-dementiaOpen linkView original on sh.itjust.works
9 replies
People who passed health based selection to trial new medications were found to be healthy.
They got that dawg in 'em
I admittedly didn't read the article (no time as I speak), but surely they included a control group?
In truth I didn't it read either, I was just making a glib comment. I do know that unlike the rest of science medical science dealing with people often selects patients via hospitals and this introduces bias, intentional or hopefully accidental into the selection process. A great deal of patient history is known during selection, unhealthy patients not chosen for trial drugs but allowed onto the control. Maybe I am just getting cynical.
Increased risk of arthritic conditions sounds pretty bad...
Compared to psychosis and dementia?
Depends what the comparative offsets are
I have arthritis and the beginning stages of dementia.
Trust me when I say the later is worse because there's nothing I can do about it.
I'm not doubting which thing is worse, dementia is certainly worse, I just mean that we don't know how affective the drug is against dementia.